Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51).
- Citation:
- Lung Cancer vol 60 (2) 200-7
- Year:
- 2008
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- None
- Children:
- None
- Program:
- OGC
- Primary Committee:
- Respiratory
- Sec. Committees:
- Pharmas:
- Grants:
- CA-25224, CA-35101, CA-35103, CA-35113, CA-35119, CA-35195, CA-35269, CA-35431, CA-35448, CA-37404, CA-37417, CA-60276, CA-63848, CA-63849
- Corr. Author:
- Authors:
- Elizabeth A Johnson Randolph S Marks Sumithra J Mandrekar Shauna L Hillman Mark D Hauge Mitchel D Bauman Edward J Wos Dennis F Moore John W Kugler Harold E Windschitl David L Graham Albert M Bernath Tom R Fitch Gamini S Soori James R Jett Alex A Adjei Edith A Perez
- Networks:
- Study
- NCCTG-972451
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords:
- Aged, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Double-Blind Method, Female, Humans, Kaplan-Meier Estimate, Lung Neoplasms, Male, Middle Aged, Placebos, Quality of Life, Triazoles